You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Therapeutic Antibodies for Biofilm Infections
SBC: TRELLIS BIOSCIENCE, INC. Topic: NIAIDDESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A new generation of targeted therapeutics for the treatment of cancer
SBC: NERX BIOSCIENCES, INC. Topic: NCIDESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder
SBC: Biomedical Development Corporation Topic: 103DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system
SBC: FasCure Therapeutics LLC Topic: NIAIDDESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Mechanistic Studies of a Novel Small Molecule HIV Inhibitor
SBC: ADVANCED GENETIC SYSTEMS, INC. Topic: 100DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a biomimetic small molecule therapeutic for neovascular retinal diseases
SBC: EyeMedix, Inc. Topic: NDESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography
SBC: Vibronix, Inc. Topic: 102DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
SBC: XFIBRA, LLC Topic: NHLBIDESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: 102DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Membrane Protein Solubilization/Stabilization Screen
SBC: SOLUBLE THERAPEUTICS, INC Topic: 100DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health